AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory

While most eyes were on AstraZeneca's keenly awaited MYSTIC lung cancer study of Imfinzi, its PACIFIC trial has ducked under the radar and hit investors with the nicest kind of surprise. The results could have wider implications for IO in earlier-stage cancers.

AstraZeneca PLC surprised the market with the unexpectedly early and positive results from its Phase III PACIFIC study of the newest PD-L1 blocker on the market, Imfinzi (durvalumab), in Stage III lung cancer. Its shares were up by more than 4.6% on the London Stock Exchange on the morning of May 12 as the added commercial opportunity sank in.

Not only do the results provide a fillip to AstraZeneca's immuno-oncology franchise by potentially securing first dibs on an NSCLC market segment that could have blockbuster potential in its own...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

29 May 2025

• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

29 May 2025

• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.

GSK’s Bet On Spero’s Oral cUTI Antibiotic Poised To Pay Off With New Phase III Data

28 May 2025

• By Joseph Haas

Spero and partner GSK have Phase III non-inferiority data to support approval of tebipenem as the first oral antibiotic for complicated urinary tract infections.